These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 28428040

  • 1. Design, synthesis, and docking studies of quinazoline analogues bearing aryl semicarbazone scaffolds as potent EGFR inhibitors.
    Tu Y, Wang C, Xu S, Lan Z, Li W, Han J, Zhou Y, Zheng P, Zhu W.
    Bioorg Med Chem; 2017 Jun 15; 25(12):3148-3157. PubMed ID: 28428040
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Design, synthesis, antiproliferative activity and docking studies of quinazoline derivatives bearing 2,3-dihydro-indole or 1,2,3,4-tetrahydroquinoline as potential EGFR inhibitors.
    OuYang Y, Zou W, Peng L, Yang Z, Tang Q, Chen M, Jia S, Zhang H, Lan Z, Zheng P, Zhu W.
    Eur J Med Chem; 2018 Jun 25; 154():29-43. PubMed ID: 29775935
    [Abstract] [Full Text] [Related]

  • 4. Novel morpholin-3-one fused quinazoline derivatives as EGFR tyrosine kinase inhibitors.
    Qin X, Lv Y, Liu P, Li Z, Hu L, Zeng C, Yang L.
    Bioorg Med Chem Lett; 2016 Mar 15; 26(6):1571-1575. PubMed ID: 26879314
    [Abstract] [Full Text] [Related]

  • 5. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Wang J, Tang Q, Wu C, Zhao Y, Zheng P.
    Bioorg Med Chem; 2016 Apr 15; 24(8):1749-56. PubMed ID: 26964675
    [Abstract] [Full Text] [Related]

  • 6. Development of a series of novel 4-anlinoquinazoline derivatives possessing quinazoline skeleton: Design, synthesis, EGFR kinase inhibitory efficacy, and evaluation of anticancer activities in vitro.
    Chang J, Ren H, Zhao M, Chong Y, Zhao W, He Y, Zhao Y, Zhang H, Qi C.
    Eur J Med Chem; 2017 Sep 29; 138():669-688. PubMed ID: 28711702
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W, Wang W, Xu S, Tang Q, Luo R, Wang M, Gong P, Zheng P.
    Bioorg Med Chem; 2016 Feb 15; 24(4):812-9. PubMed ID: 26810712
    [Abstract] [Full Text] [Related]

  • 9. Discovery of novel quinazoline derivatives bearing semicarbazone moiety as potent EGFR kinase inhibitors.
    Tu Y, Wang C, Yang Z, Zhao B, Lai L, Yang Q, Zheng P, Zhu W.
    Comput Struct Biotechnol J; 2018 Feb 15; 16():462-478. PubMed ID: 30455856
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Design, synthesis, antiproliferative activity, molecular docking and cell cycle analysis of some novel (morpholinosulfonyl) isatins with potential EGFR inhibitory activity.
    Ammar YA, Sh El-Sharief AM, Belal A, Abbas SY, Mohamed YA, Mehany ABM, Ragab A.
    Eur J Med Chem; 2018 Aug 05; 156():918-932. PubMed ID: 30096580
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
    Wang C, Xu S, Peng L, Zhang B, Zhang H, Hu Y, Zheng P, Zhu W.
    J Enzyme Inhib Med Chem; 2019 Dec 05; 34(1):203-217. PubMed ID: 30835140
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X, Bao G, Wang L, Cheng M, Zhao M, Zhao S, Zhou H, Gong P.
    Bioorg Med Chem; 2016 Mar 15; 24(6):1331-45. PubMed ID: 26897090
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
    Zhou Z, He J, Yang F, Pan Q, Yang Z, Zheng P, Xu S, Zhu W.
    Bioorg Chem; 2021 Jul 15; 112():104848. PubMed ID: 33819737
    [Abstract] [Full Text] [Related]

  • 19. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P, Chu J, Li Y, Wang Y, He Y, Qi C, Chang J.
    Bioorg Med Chem; 2019 Oct 15; 27(20):114938. PubMed ID: 31488358
    [Abstract] [Full Text] [Related]

  • 20. Novel series of 6-(2-substitutedacetamido)-4-anilinoquinazolines as EGFR-ERK signal transduction inhibitors in MCF-7 breast cancer cells.
    Ismail RSM, Abou-Seri SM, Eldehna WM, Ismail NSM, Elgazwi SM, Ghabbour HA, Ahmed MS, Halaweish FT, Abou El Ella DA.
    Eur J Med Chem; 2018 Jul 15; 155():782-796. PubMed ID: 30047410
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.